Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.60
Bid: 111.00
Ask: 111.40
Change: -0.40 (-0.36%)
Spread: 0.40 (0.36%)
Open: 111.00
High: 111.80
Low: 110.40
Prev. Close: 111.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of shares per 2019 dividend & PDMR dealings

18 Jul 2019 15:51

RNS Number : 0316G
Syncona Limited
18 July 2019
 

Syncona Limited

 

Issue of shares pursuant to the 2019 dividend and PDMR dealings

 

18 July 2019

 

Syncona Limited (the "Company") today announces that a total of 860,090 new ordinary shares will be issued in satisfaction of the payment of the Company's 2019 dividend to those qualifying shareholders who did not elect to receive the dividend in cash. The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. 

 

Application has been made to the Financial Conduct Authority for the shares to be admitted to the Official List, and to the London Stock Exchange for the shares to be admitted to trading and it is expected that dealings will commence in the new ordinary shares on 29 July 2019.

 

Notification of transactions by Persons Discharging Managerial Responsibilities ("PDMRs") are set out below.

 

[ENDS]

 

Enquiries

 

Syncona Ltd

Siobhan Weaver / Annabel Clay

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

Brett Pollard / Natalie Garland-Collins

Tel: +44 (0) 20 3727 1000

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com

About Syncona:

 

Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

 

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.

 

We take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of genetic medicine, particularly gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Martin Murphy

b)

Position / status

Chief Executive Officer, SIML

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Acquisition of shares under the 2019 Dividend

c)

Price(s) and volume(s)

Price(s)

Volume(s)

2.281

3,094

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

18 July 2019

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Jeremy Tigue

b)

Position / status

Chairman

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Acquisition of shares under the 2019 Dividend

c)

Price(s) and volume(s)

Price(s)

Volume(s)

2.281

4,820

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

18 July 2019

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Ellen Strahlman

b)

Position / status

Non-Executive Director

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Acquisition of shares under the 2019 Dividend

c)

Price(s) and volume(s)

Price(s)

Volume(s)

2.281

1,584

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

18 July 2019

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Robert Hutchinson

b)

Position / status

Non-Executive Director

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Acquisition of shares under the 2019 Dividend

c)

Price(s) and volume(s)

Price(s)

Volume(s)

2.281

432

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

18 July 2019

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOELLFSSDAITLIA
Date   Source Headline
31st May 20241:51 pmRNSAutolus presents FELIX data at ASCO
31st May 20247:00 amRNSTransaction in Own Shares
30th May 20247:00 amRNSTransaction in Own Shares
29th May 20247:00 amRNSTransaction in Own Shares
28th May 20247:00 amRNSTransaction in Own Shares
24th May 20247:00 amRNSTransaction in Own Shares
23rd May 20247:00 amRNSNotice of Results
23rd May 20247:00 amRNSTransaction in Own Shares
22nd May 20247:00 amRNSTransaction in Own Shares
21st May 20247:00 amRNSTransaction in Own Shares
20th May 20247:00 amRNSTransaction in Own Shares
17th May 202412:05 pmRNSAutolus reports Q1 2024 Financial Results
17th May 20247:00 amRNSTransaction in Own Shares
16th May 20247:00 amRNSTransaction in Own Shares
15th May 20247:00 amRNSTransaction in Own Shares
14th May 20247:00 amRNSTransaction in Own Shares
13th May 20247:00 amRNSTransaction in Own Shares
10th May 20247:00 amRNSTransaction in Own Shares
9th May 202411:05 amRNSFreeline presents clinical data update
9th May 20247:00 amRNSTransaction in Own Shares
8th May 202412:11 pmRNSAchilles reports Q1 2024 Financial Results
8th May 20247:00 amRNSTransaction in Own Shares
7th May 20247:00 amRNSTransaction in Own Shares
3rd May 20247:00 amRNSTransaction in Own Shares
2nd May 20247:00 amRNSTransaction in Own Shares
1st May 20242:14 pmRNSTotal Voting Rights
1st May 20247:00 amRNSTransaction in Own Shares
30th Apr 20247:00 amRNSTransaction in Own Shares
29th Apr 20247:00 amRNSTransaction in Own Shares
25th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
23rd Apr 20247:00 amRNSTransaction in Own Shares
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 202412:02 pmRNSCentury Therapeutics to acquire Clade Therapeutics
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 202411:50 amRNSAchilles reports full year 2023 Financial Results
4th Apr 202411:47 amRNSAchilles provides clinical data update
4th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20242:45 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.